Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Daryl Scott Lab, |
RCV002601334 | SCV007114123 | uncertain significance | Mucopolysaccharidosis, MPS-II | 2025-08-25 | criteria provided, single submitter | clinical testing | PP3 |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV003226549 | SCV003922569 | uncertain significance | not specified | 2023-03-29 | criteria provided, single submitter | clinical testing | Variant summary: IDS c.575C>G (p.Pro192Arg) results in a non-conservative amino acid change located in the Sulfatase, N-terminal (IPR000917) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.7e-05 in 183401 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.575C>G in individuals affected with Mucopolysaccharidosis Type II (Hunter Syndrome) and no experimental evidence demonstrating its impact on protein function have been reported. Two submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as likely benign, and one laboratory classified it as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. |
| Baylor Genetics | RCV002601334 | SCV003834932 | uncertain significance | Mucopolysaccharidosis, MPS-II | 2021-03-25 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV002601334 | SCV002951815 | likely benign | Mucopolysaccharidosis, MPS-II | 2026-01-06 | criteria provided, single submitter | clinical testing |